STAAR Surgical Co. - Q1 2000 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2000. STAAR Surgical Company is a Delaware corporation engaged in the development, manufacture, and sale of intraocular lenses (IOLs) and refractive products, including the Implantable Contact Lens and Toric intraocular lens. The company also operates laser eye centers.
Key Financial Metrics
| Metric | Q1 2000 | Q1 1999 |
|---|---|---|
| Total Revenues | $14.14 million | $14.78 million |
| Gross Profit | $8.66 million (61.2% margin) | $9.04 million (61.1% margin) |
| Operating Income | $0.34 million | $1.39 million |
| Net Income | $0.26 million ($0.02/share) | $0.67 million ($0.05/share) |
| Cash and Equivalents | $3.42 million | $4.10 million |
| Net Cash Used in Operating Activities | ($1.58 million) | ($0.02 million) |
| Total Debt (Current + Long-term) | $20.13 million | N/A (Derived from prior period) |
| Current Ratio | 2.6:1 | 2.4:1 (Dec 31, 1999) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 4.4% year-over-year. This was driven by lower unit sales of IOLs in Europe and Asia, competitive pricing pressures, and a stronger U.S. dollar. These declines were partially offset by increased sales of refractive products and laser center operations.
- Profitability Compression: Net income fell 60.8% to $263,545. Operating income dropped 75.5% due to a 34.2% increase in General and Administrative expenses (as a percentage of revenue) and higher R&D costs for clinical trials.
- Debt Increase: The company secured a new $7.0 million term loan during the quarter. Total debt increased significantly, though the company maintains a current ratio of 2.6:1.
- Asset Growth: Patents and licenses increased by approximately $2.9 million due to the acquisition of new technology (partially paid in stock). Inventories rose to $24.1 million in preparation for the U.S. launch of the Collamer intraocular lens.
Outlook, Risks, and Unusual Items
- Restructuring Plan: Subsequent to the quarter, the Board preliminarily approved a financial restructuring plan expected to incur one-time charges of $15.0 million to $17.0 million in Q2 2000. These charges will include write-offs of the Canon STAAR joint venture investment, under-performing subsidiaries, obsolete patents, inventory, and laser center investments.
- Covenant Compliance: The company was not in compliance with restrictive covenants of its new term loan as of March 31, 2000. Management is negotiating adjustments with the lender to ensure future compliance.
- Cost Reduction: Management has initiated an aggressive cost reduction program, including changes in manufacturing management, with benefits expected late in 2000 or early 2001.
- Foreign Exchange Risk: The company faces risks from fluctuating exchange rates, particularly regarding its principal foreign market in Europe.
Investor Verification Checklist
- Verify the status of negotiations with the lender regarding the covenant waiver for the $7.0 million term loan.
- Confirm the specific components and timing of the anticipated $15.0–$17.0 million restructuring charges in Q2 2000.
- Monitor the success of the new cost reduction program and its impact on the cost of sales margin.
- Assess the impact of the write-off of the Canon STAAR joint venture on future earnings and strategic partnerships.
- Review the inventory levels ($24.1 million) relative to the upcoming Collamer lens launch to ensure no further obsolescence charges are needed.